Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC
| dc.contributor.author | Enquist, Ida | |
| dc.contributor.author | Kotnatsubara, Kim | |
| dc.contributor.author | Deng, Yu | |
| dc.contributor.author | Kuriki, Hiroshi | |
| dc.contributor.author | Wen, Xiaohui | |
| dc.contributor.author | Jassem, Jacek | |
| dc.contributor.author | Reinmuth, Niels | |
| dc.contributor.author | Spigel, David | |
| dc.contributor.author | De Marinis, Filippo | |
| dc.contributor.author | Giaccone, Giuseppe | |
| dc.contributor.author | Verynenegre, Alain | |
| dc.contributor.author | Barrios, Carlos Henrique | |
| dc.contributor.author | Morise, Masahiro | |
| dc.contributor.author | Felip, Enriqueta | |
| dc.contributor.author | Andric, Zoran | |
| dc.contributor.author | Geater, Sarayut | |
| dc.contributor.author | Ozgueroglur, Mustafa | |
| dc.contributor.author | Mocci, Simonetta | |
| dc.contributor.author | Mccleland, Mark | |
| dc.contributor.author | Herbst, Roy S. | |
| dc.date.accessioned | 2021-03-05T18:32:12Z | |
| dc.date.available | 2021-03-05T18:32:12Z | |
| dc.identifier.citation | Reinmuth N., Spigel D., De Marinis F., Giaccone G., Verynenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., Geater S., et al., "Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC", ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.232-233, 2020 | |
| dc.identifier.issn | 2296-5270 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_cacec438-672a-4d4b-ba1a-9da01b4e77a6 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/134353 | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.title | Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC | |
| dc.type | Makale | |
| dc.relation.journal | ONCOLOGY RESEARCH AND TREATMENT | |
| dc.contributor.department | Roche Holding , , | |
| dc.identifier.volume | 43 | |
| dc.identifier.startpage | 232 | |
| dc.identifier.endpage | 233 | |
| dc.contributor.firstauthorID | 2277643 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Makale [92796]
